Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Concise Method
Hypothesis 1: Pro-ACH responders will account for the majority of the participants
Ask a
question
Favorite
When participants were asked which categories of drugs gave them hope for a treatment of AD, if they answered “BACE inhibitors” and/or “Anti-Aβ antibodies” (which we combine in Results as “ACH drugs”) and also considered “Aβ physiology (production, clearance, etc.)” to be the number 1 priority in pre-clinical, early, or late stage AD, then they were considered to be “pro-ACH.”
Copyright and License information: ©2021 – The authors. Published by IOS Press
This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
